SEC Form 4 · accession 0001104659-26-079792
Nuvectis Pharma, Inc. · NVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ron Bentsur
Officer — Chairman & CEO · Director · 10% Owner
Period of report
Jun 30, 2026
Accepted (ET)
Jul 1, 2026 · 1:39 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001875558
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 30, 2026 | P | 12,500 | $20.00 | A | 3,688,424 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026.
- F2Includes shares of restricted common stock.